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Summary
The ERBB2 gene codes for p185erbB2, a transmembrane protein with intrinsic tyrosine kinase activity. P185erbB2 is a
member of the EGFR family of growth factor receptors. The gene is expressed in embryonic and adult cells and its
function is necessary throughout the entire life. ERBB2 is overexpressed in a significant proportion of human breast
cancers where it is correlated to poor prognosis for the patient. The gene is also overexpressed in non-breast cancers
but researchers disagree on the prognostic significance of the overexpression in these cancers. Gene amplification
and increased transcription rates account for the very high levels of p185erbB2 accumulated in breast cancer cells. In
a proportion of breast cancer cells a moderate increase in p185erbB2 level is due to transcriptional deregulation alone.
The mechanisms responsible for ERBB2 gene overexpression in non-breast cancer cells is not well understood. The
molecular mechanisms responsible for ERBB2 gene overexpression have been investigated mostly in breast cancers.
In this paper we review the data from the literature and our own results on the involvement of the AP-2
transcription factors family in ERBB2 gene overexpression in breast cancer cells. We conclude that AP-2 family of
transcription factors contribute to the ERBB2 overexpression in a fraction of breast cancers. In contrast, AP-2
factors are not responsible for increased ERBB2 expression in the non-breast cancer cells we have analyzed.
I. Introduction: the ERBB network
The ERBB2 gene (also known as HER2 or Neu)
encodes a 185 kDa transmembrane protein, p185erbB2, with
intrinsic tyrosine kinase activity. P185erbB2 belongs to the
EGF receptor (ErbB1) family of tyrosine kinase receptors,
along with the products of EGFR, ERBB3 and ERBB4
genes. ErbB -1, -3 and -4 are recognized by more than 20
growth factors belonging to the EGF family. Ligand bound
receptors form homodimers and/or heterodimers
composed of two different receptors of the EGFR family.
No soluble growth factor recognizing p185erbB2 with high
affinity has been identified so far and p185erbB2 is thus
considered as an “orphan receptor”. The enzymatic
activity of the ERBB3 gene product is impaired by
mutation in the tyrosine kinase domain. P185erbB2 and the
ERBB3 gene product are activated by hetero-dimerisation
with another active ligand-bound receptor (reviewed in
Brennan et al, 2000; Harari and Yarden, 2000; Olayioye et
al, 2000; Yarden and Sliwkowski, 2001; Citri et al, 2003;
Casalini et al, 2004).
The ErbB receptors together with the EGF family of
ligands form the ErbB signaling network. In the healthy
tissues the ligands are secreted by stromal cells and bind
receptors present on the surface of epithelial cells (Burden
and Yarden, 1997).
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Once activated, tyrosine residues at the carboxyl-end
of the receptors are phosphorylated, creating docking sites
for cytoplasmic signalling molecules. This triggers several
signalling cascades, resulting in differentiation, survival,
migration, depending on the growth factor, the
composition of the dimer and the signalling molecules
present in the cell.
P185erbB2 is the preferred dimerisation partner for the
three other receptors of the ErbB family. The heterodimers
containing p185erbB2 last longer and are more active than all
the other homo- or heterodimers. High levels of p185erbB2,
such as those measured in cancerous cells overexpressing
the gene stimulate proliferation, inhibit apoptosis, induce
migration and modify the response to chemo- and
hormone- therapy (reviewed in Harari and Yarden, 2000;
Olayioye et al, 2000; Yarden and Sliwkowski, 2001).
Here we summarize first some data on the normal
ERBB2 gene expression and functions. The following
section presents an overview of ERBB2 gene
overexpression in breast and non-breast cancers. The
molecular mechanisms leading to ERBB2 overexpression
are the main topic of this paper. We present our data on
ERBB2 overexpression in breast cancer cells. We discuss
our results and the data from the literature concerning the
role of AP-2 transcription factors on ERBB2 gene
overexpression. Our results on the overexpression in non-
breast cancers are summarised in the last section of this
paper.
II. ERBB2 expression in healthy
tissues
Low levels of membranous p185erbB2 were detected in
epithelial cells of a variety of normal human tissues such
as those of the gastro-intestinal, respiratory, reproductive
and urinary tracti, as well as in skin, breast and placenta
(Press et al, 1990; King et al, 1992; Camp et al, 2003).
An intact ErbB signaling network is required during
embryonic development and throughout the entire life of
an animal. Mice embryos carrying knocked-out ErbB2
gene died as a consequence of defects in the development
of the heart and the nervous system. Animals where the
ErbB2 gene was inactivated specifically in the heart after
birth developed dilated cardiomyopathy. Formation of
neuromuscular synapses, development of muscle spindles,
Schwann cell function and survival of motor neurons were
impaired in ErbB2 deficient mice (reviewed by Garratt et
al, 2003; Holbro and Hynes, 2004). ErbB2 gene expressed
in mice colon epithelial cells ensured the survival of
enteric neurons and glia (Crone et al, 2003). In the inner
ear, ErbB2 expressed by supporting cells ensured the
survival of spiral ganglion neurons (Stankovic et al, 2004).
The differentiating virgin mouse mammary glands express
and activate ErbB2. The receptor drives the alveolar
differentiation during pregnancy (reviewed by Troyer and
Lee, 2001; Stern, 2003).
P185erbB2 levels are physiologically modulated in
healthy tissues and in non-cancerous pathologies. Erbb2
expression was increased in the regenerating mice
intestine after small bowel resection (Falcone et al, 1999).
During the maturation of the mice (Schroeder and Lee,
1998) and rat (Darcy et al, 2000) mammary gland changes
in cell types expressing p185erbB2 and expression levels
were observed. Variations in p185erbB2 levels during the
menstrual cycle in the adult human breast were described.
The protein was more abundant during the luteal than
during the follicular phase of the cycle (Gompel et al,
1996).
III. ERBB2 overexpression in cancers
Not surprisingly given the importance of the cellular
processes it regulates, the ErbB signalling network plays a
central role in the development of numerous human
cancers. Indeed, shortly after the discovery of the ErbB2
gene (Neu) as an oncogene in chemically induced rat brain
cancers, Slamon and co-workers described the
amplification and overexpression of the corresponding
human gene in breast and ovary cancers. Moreover, the
overexpression was associated with a poor prognosis
(reviewed by DiGiovanna, 1999). This initial observation
has been confirmed since by numerous studies and lead to
the development of p185erbB2 targeted therapies for breast
cancer (Ross et al, 2003). Interestingly, ErbB2
overexpression was reported recently in spontaneous
canine (de la Mulas et al, 2003) and feline (De Maria et al,
2005) mammary cancers. In both species this was a poor
prognostic factor.
ERBB2 gene overexpression was also observed in
non-breast human cancers, such as Wilm’s tumours,
bladder, pancreas, colon, lung and prostate cancers. The
prognostic significance of ERBB2 gene overexpression in
non-breast tumours is debated (Klapper et al, 2000;
Menard et al, 2001).
Twenty to forty percent of ovary cancers were
reported to overexpress ERBB2 (Kupryjanczyk et al,
2004). The overexpression was most frequent in metastatic
ovary carcinoma specimen and cancer cell lines
(Hellström et al, 2001). In a subset of ovarian cancers the
gene was amplified but not overexpressed (Wu et al,
2004). ERBB2 overexpression was shown to be necessary
for the growth of the ovarian cancer cells (Juhl et al, 1997;
Hsieh et al, 2000) and might condition the response to
chemotherapy (Abuharbeid et al, 2004).
ERBB2 status in other types of human cancer is
controversial, mostly because of methodological problems.
Maurer et al, (1998) reported co-expression of
ERBB2 and ERBB3 genes in a high proportion of primary
colorectal cancers. This was interesting since in breast
cancers the erbB2/erbB3 dimer was shown to be the most
tumorigenic (Harari and Yarden, 2000). Vadlamudi and
co-workers (1999) further showed that these receptors
were constitutively phosphorylated in colon cancer cells.
However, other investigators detected ERBB2 gene
amplification and overexpression only in a small
proportion of primary human colon cancers (Nathanson el
al, 2003; Half et al, 2004).
Increased p185erbB2 levels were detected by IHC in
ductal pancreatic adenocarcinoma (Apple et al, 1999;
work cited by Hruban et al, 2000). In contrast, Koeppen et
al, (2001) did not observe a significant increase in
p185erbB2 levels in pancreatic cancers.
According to Craft et al, (1999) and to Signoretti et
al. (2000) ERBB2 expression was increased in prostate
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cancer cells after androgen ablation and in hormone
independent cancers. Some authors confirmed these
observations (Osman et al, 2001; Shi et al, 2001). P185erbB2
overexpression might thus contribute to progression
toward androgen independence. The high p185erbB2 levels
detected in a significant proportion of circulating prostate
cancer cells supported a role for the oncogene in prostate
cancer progression (Ady et al, 2004; Carles et al, 2004).
However, no consensus has been reached yet as to the role
of ERBB2 in the progression of hormone independent
prostate cancers, since other investigators did not observe
a correlation between ERBB2 expression and hormone
sensitivity (Reese et al, 2001; Savinainen et al, 2002;
Calvo et al, 2003). The discrepancy between the results is
probably due to methodological problems (Sanchez et al,
2002).
In summary, the involvement of ERBB2 gene
overexpression in breast and ovary cancers progression is
generally accepted. Breast cancer cells contain very high
amounts of p185erbB2 as a consequence of gene
amplification combined with increased transcription rates.
P185erbB2 targeted therapies are developed for the treatment
of breast cancer patients with ERBB2 overexpression.
Whether ERBB2 gene overexpression is significantly
involved in non-breast tumours progression is less clear.
When present, the increase in p185erbB2 levels in most of
these tumours was moderate and the methodological
problems concerning the detection of ERBB2 gene
overexpression are not solved.
IV. Molecular mechanisms leading to
ERBB2 overexpression in breast cancers
The mechanisms responsible for ERBB2 gene
overexpression were investigated almost exclusively in
breast cancers. Gene amplification and increased
transcription rates lead to the very high increase in erbB2
transcript and protein levels in breast cancers. Moderate
overexpression was often the consequence of
transcriptional deregulation alone (Jimenez et al, 2000;
Pauletti et al, 2000; Ménard et al, 2001; Hammock et al,
2003; Merkelbach-Bruse et al, 2003; Owens et al, 2004).
We did show by run-on experiments, increased
transcription rates in breast cancer cells overexpressing
ERBB2 (Pasleau et al, 1993).
Several teams, including our own, are interested in
unravelling the mechanisms of deregulated ERBB2
transcription in breast cancer cells.
Briefly, transcription rates are controlled by binding
of transcription factors to specific enhancer sequences on
the promoter. Transcription factors bound to regulatory
sequences (enhancers or silencers) interact directly or
indirectly with general transcription factors which recruit
RNA polymerase II to the core promoter. Transcription
rates can be increased by different mechanisms: increased
levels or activity of transcription factors; mutations in the
promoter creating binding sequences for a new activator or
disrupting the binding site for a repressor. Recently,
epigenetic mechanisms – DNA and histone methylation,
histone acetylation – were involved in gene expression
levels modulations.
To the best of our knowledge no mutations of the
ERBB2 promoter have been reported in the cancerous cells
overexpressing the gene. In contrast, overexpression and
activation of transcription factors have been involved in
ERBB2 overexpression in breast cancer cells.
W  have analyzed the transcriptional activity of a
6kb fragment of the ERBB2 promoter. After describing the
general transcriptional elements on the promoter, we focus
on our data and the results from the literature concerning
th  role of increased levels of AP-2 transcription factors
on ERBB2 overexpression.
A. General transcriptional elements on
the human ERBB2 promoter
Three independent transcription start sites have been
mapped on the ERBB2 gene promoter (Figure 1A). First, a
TATA (-22 to -26) and a CAAT (-71 to -75) box direct
transcription initiation at the site marked +1. This site will
be referred to as the main transcription start site. An
initiator like region (Inr), consisting of six GGA
polypurine / polypyrimidine repeats, located from -65 to -
45 base pairs upstream of the major transcription start site
directs a second set of transcription start sites. The TATA
box and the Inr independently govern the initiation of
transcription (Mizuguchi et al, 1994). A third set of
transcription initiation sites has been identified recently
12kb upstream from the main transcription start site. The
mRNA initiated at this upstream site was present in low
amounts in all the tested cells. It has an original 5’
untranslated region and encodes a protein that is identical
t  the one translated from the major transcripts (Nezu et al,
1999).
The polypurine (GGA)-polypyrimidine (TTC) rich
region forms an internal triplex structure (H-DNA) that
represses ERBB2 gene transcription (Scott et al, 2000).
An approximately 500bp sequence at the 5’ end of
the 6kb fragment contains multiple AA, TA and CA
dinucleotide repeats. These features are characteristic of
DNA sequences associated with the nuclear matrix and
mediate the attachment of chromatin loops to the nuclear
matrix (Laemmli et al, 1992). These Matrix Attachment
Regions (MAR) have been involved in important cellular
processes such as transcription activation (Bode et al,
2000) or insulation of genes from position effects (Allen et
al, 2000).
We analyzed the sequence of a 20kb fragment of the
human ERBB2 promoter with the MAR-finder program
(Singh et al, 1997) to find out if the region containing the
repeats has indeed the characteristics of a MAR. A
maximal MAR potential was revealed in the region
located between the positions -6/-5.6kb upstream from the
main transcription start site (Figure 1B). This region of
the ERBB2 promoter could thus be implicated in the
regulation of ERBB2 transcription by organizing the
chromatin domain containing the gene. Interestingly, a
DNase hypersensitive site has been previously localized
around position -5.5kb, indicating that this chromatin
region is accessible to DNA binding factors (Vernimmen,
unpublished). The accessibility is essential for MAR
sequences that often co-localize with DNaseI
hypersensitive sites (Bode et al, 2000).
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B. Regulated transcriptional elements of
the ERBB2 promoter
1. The proximal promoter
The transcriptional activity of the proximal 500bp of
the ERBB2 promoter was in good agreement with the level
of expression of the endogenous gene in different breast
cancer cell lines (Hollywood and Hurst, 1993; Grooteclaes
et al, 1994; Scott et al, 1994).
Three binding sites for transcription factors
implicated in the overexpression of the gene have been
localized on the proximal promoter. An ETS binding site
(EBS) was located immediately upstream the TATA box
(Scott et al, 2000) and two AP-2 binding sites (AP2BS)
were located 213 (Bosher et al, 1996) and 495bp upstream
from the transcription start site (Grooteclaes et al, 1994;
1999; Vernimmen et al, 2003a) (Figure 1C).
Figure 1. A. General transcriptional elements on 12kb of the human ERBB2 promoter. The broken arrows indicate the transcription start
sites. The start site at position +1 is considered as the main transcription start site of the human gene. GGA: region containing the GGA
repeats corresponding to the Initiator element (Inr). The gray box indicates the region containing the dinucleotide repeats. B. MAR
potential analysis of the ERBB2 promoter. Positions are given relative to the major transcription start site. The sequence of an 18kb
fragment of the human ERBB2 promoter was reconstituted from Z13970 (Hudson et al, 1990), X56495 (Grooteclaes et al, 1994) and
AB025285 (Nezu et al, 1999) sequences. C. R gulated transcriptional elements of the ERBB2 promoter. Broken arrows indicate the
transcription start sites. Positions of the EBS and AP2BS associated with ERBB2 overexpression are indicated. The arrows point to the
extremities of the promoter fragments which have been tested for activity. The plus signs indicate the promoter fragments active in the
breast cancer cells which overexpress ERBB2. The minus signs indicate the repressing fragments. ± indicates a fragment which has
different transcriptional activity according to the cell line.
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The identity of the Ets transcription factor
responsible for ERBB2 overexpression is not precised yet.
Several members of this vast family of transcription
factors, such as ESX, are overexpressed and/or activated
in breast cancer cells which overexpress ERBB2 (Chang et
al, 1997).
The AP-2 family of transcription factors includes
five members: AP-2 -a, ß, -g (Bosher et al, 1996), -d
(Cheng et al, 2002) and -e (Tummala et al, 2003). Breast
cancer cell lines overexpressing ERBB2 contain high
amounts of AP-2 -a and -g factors (Bosher et al, 1995;
1996; Grooteclaes et al, 1999).
We assessed the contribution of the -495 AP2BS to
the promoter activity. For this purpose, we used a reporter
vector containing the luciferase cDNA under the control of
the proximal 750bp of the ERBB2 promoter. New vectors
were derived from the initial one where each one or both
AP2BS were inactivated by site-directed mutagenesis.
Mutating the AP-2 sites, either individually or in
combination, reduced the activity of the promoter to one
fifth the activity of the wild type promoter. Thus, both AP-
2 sites must be present for full promoter activity
(Vernimmen et al, 2003a).
2. Distant regulatory regions
We have investigated the transcriptional activity of
promoter regions located upstream the proximal promoter
(Figure 1C). The 3.5kb fragment preceding the proximal
promoter repressed its activity in most cells. The
mechanism of repression remains to be precised. The
further upstream 2.2kb fragment reversed the repression
specifically in breast cancer cells overexpressing ERBB2
(Grooteclaes et al, 1994; Delacroix et al, in press).
The distal promoter region contains two AP-2
binding sites (Figure 1C). Binding of the factors to these
sites contributed to the activity of the fragment. Indeed,
the region of the distal activating fragment containing the
two distal AP2BS was able to stimulate transcription from
a heterologous TK promoter (Delacroix et al, in press).
Thus, the ERBB2 promoter contains at least four AP-
2 binding sites, which contribute to the overexpression of
the gene in breast cancer cells (Figure 1C). To evaluate
the contribution of AP-2 factors to the transcriptional
activity of the entire 6kb fragment of the ERBB2 promoter,
we expressed an amino-terminal truncated AP-2 protein
with dominant negative activity (DN-AP2). DN-AP2 has
conserved the dimerisation and DNA binding domains, but
lacks the transactivation domain (Williams and Tjian,
1991). BT-474 and ZR-75-1 breast cancer cells,
overexpressing ERBB2 and containing high amounts of
endogenous AP-a and -g, were co-transfected with a
constant amount of a reporter vector containing the 6kb
promoter fragment and increasing amounts of the DN-AP2
expression vector. We measured a dose dependent
decrease in the activity of the ERBB2promoter, reaching
half of the activity measured in the absence of the
inhibitor. This shows that AP-2 factors contribute
significantly to the activity of the ERBB2 promoter
(Delacroix et al, in press).
C. The rodent Neu promoter
The promoters of the Neu genes, the rat and mice
orthologs of the human ERBB2 gene, have been sequenced
and the sequences were compared to those of the human
promoter. The sequences of proximal promoters,
extending 200bp upstream from the human main
transcription start site are well conserved in the three
promoters (White et al, 1992). However, there are some
important differences between these sequences, indicating
that the regulation of the human and the rodent genes
expression might differ. For instance, the N u promoters
lack the TATA box and there is no initiation of
transcription at the sites marked +1 on the human
promoter. Moreover, some regulatory sites mapped on the
rodent proximal promoters have not been found to regulate
the activity of the human promoter (reviewed by Barnes
and Hurst, 1997). Interestingly, as shown in Figure 2A,
the two proximal AP-2 binding sites are not conserved in
the rodent promoters.
A multalin alignment of the regions extending
upstream the proximal 200bp revealed very limited
sequence identity between the human, mouse and rat
ERBB2 promoters (not shown). We also analyzed the
mouse and rat Neu gene promoter sequences with the
MAR-finder program. Indeed, several experimentally
identified MARs are present at similar positions in the
promoters of orthologous genes (Avramova et al, 1998;
Greally et al, 1999). Despite limited sequence
conservation, the potential of MAR occurrence on Neu
omoters was very high for a region overlapping the
position located 6kb upstream from the transcription start
sites (Figure 2B and C). This conserved putative MAR
sequence of ERBB2 distal promoter might thus be a
g neral regulator of ERBB2 gene expression. Noteworthy,
the effect of such a MAR cannot be detected in reporter
vectors experiments, since they are believed to act by
chr atin remodeling. Transgenic animal models or stable
transfection experiments have to be used to further study
the contribution of the distal MAR to the expression of
ERBB2 gene.
V. AP-2 transcription factors and
ERBB2 expression in breast cancer cells
AP-2 factors activate the ERBB2 promoter in reporter
vectors. These results initiated new research to find out if
these transcription factors do indeed play a role in the
overexpression of the endogenous ERBB2 gene in breast
cancer cells. Three methodologies were used to address
this question. First, AP-2 binding to the endogenous
ERBB2 promoter and the consequences of AP-2 down-
regulation on ERBB2 expression were analyzed in cultured
cells. Second, AP-2 and p185erbB2 levels, visualized by
immunohistochemistry (IHC) on primary breast cancer
sections, were compared. Third, Neu expression levels
were investigated in transgenic mice overexpressing AP-2
in the mammary gland.
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Figure 2. A. Alignment of the
human ERBB2 (-590/+183bp
relative to the main transcription
start site), the mouse (-652/+6bp
relative to the ATG translation
initiation codon) and rat Neu (-
683/+15bp relative to the ATG
translation initiation codon)
proximal promoters. The black
nucleotides are conserved, whereas
the grey nucleotides are not
conserved between the three
species. The broken line indicates
the main transcription start site on
the human promoter. The
sequences corresponding to the
human EBS and AP2BS are boxed.
B. The mouse Neu promoter
sequence from -13/+2.9kb (relative
to translation start site) isolated
from mouse BAC clone AL591390
was analyzed for the presence of
MAR. Classically, the ATG, which
is conserved in the human
sequence, is designated as position
+1 of the mouse promoter and the
transcriptional start site lies 211bp
upstream. C The rat Neu promoter
sequence comprised between
positions -9.3 and +3kb, extracted
from the rat supercontig NW-
47339.1 (Rat genome resource,
NCBI), was subjected to MAR
analysis. In the rat promoter the
ATG is located 9bp upstream the
human and mouse ATG and
defines classically the position +1.
The transcriptional start site lies at
position - 203bp.
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A. Modulation of the endogenous ERBB2
gene expression by AP-2 in breast cancer cell
lines
Binding of a transcription factor to the endogenous
chromatin embedded promoter region is the sine-qua-non
requirement for its activity. We thus checked for AP2
association to breast cancer cells endogenous ERBB2
promoter by chromatin immunoprecipitation (ChIP). The
chromatin from BT-474 cells was cross-linked, sonicated
and immunoprecipitated with an AP-2 specific antibody.
The AP-2 bound DNA fragments were PCR amplified
with primers amplifying the region containing the
proximal and the two distant AP-2 binding sites. The
results show that AP-2 factors were bound to the proximal
and the distal AP2BS (Begon et al, in press; Delacroix et
al, in press). Thus, AP-2 factors are associated to the
chromatin on the ERBB2 gene promoter in the cells
expressing the gene. However, association to the promoter
is not sufficient to prove that the factor is active.
To prove that AP-2 factors do contribute to ERBB2
overexpression, we measured ErbB2 mRNA levels in
breast cancer cells where AP-2 -a  and -g  were down-
regulated by siRNA. BT-474 breast cancer cells, which
overexpress ERBB2, were transfected with AP-2a  and AP-
2g  siRNA, independently and in combination. After two to
four days of treatment, AP-2a , AP-2g , ErbB2 and VEGF
(an AP-2 target gene) mRNAs were quantitated by real-
time RT-PCR. The results are presented in Figure 3. AP-
2a  siRNA induced a rapid down-regulation of the
corresponding protein, which became undetectable 2 days
after the treatment, while AP-2g levels were unmodified.
In contrast AP-2g  was greatly reduced in cells treated with
the specific siRNA, without significant changes in AP-2a
content. Three days after treatment with both AP-2-a  and -
g  siRNAs both factors became undetectable (Figure 3A).
The evolution of ErbB2 and VEGF transcript levels was
measured in the cells transfected with the AP-2 directed
siRNAs. Transfection with AP-2a  siRNA inhibited AP-2a
mRNA but did not modify significantly either ErbB2 or
VEGF transcript levels (Figure 3B). Comparable results
were obtained in cells transfected with AP-2-g  siRNAs
(Figure 3C). In contrast, transfection of both AP-2-a  and -
g  siRNAs induced a transitory but significant reduction in
ErbB2 and VEGF mRNA levels (Figure 3D).
In conclusion, the association of AP-2 factors with
the endogenous gene promoter and the inhibition of
expression by the down-regulation of AP-2a  and AP-2g
are strong indications that AP-2 factors do contribute to
ERBB2 overexpression in breast cancer cells. Our results
further indicate that both AP-2a  and AP-2g  are necessary
for ERBB2 overexpression. However, clearly other
transcription factors are involved in the increased ERBB2
gene expression observed in breast cancer cells (Delacroix
et al, unpublished).
Cell lines present the advantage of being easily
manipulated, however they might not reflect the properties
of primary tumours. In the next sections we summarize
results obtained on primary human breast cancers and in
transgenic mouse models.
B. Correlation between AP-2 and
p185erbB2 levels in primary breast cancers.
A first study using two antibodies recognizing
specifically AP-2a  and AP-2g  reported a positive
correlation between the levels of p185erbB2 on one hand and
the presence of both AP-2a  and AP-2g  on the other hand
(Turner et al, 1998).
A second study using a single antibody recognizing
both AP-2a  and AP-2b  found a negative correlation
between the receptor and the transcription factor levels
(Gee et al, 1999).
A third report addressed the same question using a
commercial anti AP-2a  antibody. In only a proportion of
tumours overexpressing ERBB2 were the AP-2 levels also
increased. The overall survival was shorter in patients
whos  tumours overexpressed p185erbB2 but not AP-2
(Pellikainen et al, 2004). Interestingly, we observed that in
ERBB2 overexpressing MDA-MB-453 cells, AP-2 did not
bind efficiently to DNA. ERBB2 overexpression in these
cells might not be dependent on AP-2 factors (Grooteclaes
et al, 1999).
An additional, thorough immunohistochemical
analysis localized AP-2a  and AP-2g  in healthy breast
tissues, in ductal carcinoma in situ (DCIS) and in invasive
carcinoma (IC). Higher expression levels were detected in
the healthy breast and in DCIS than in IC. Moreover, the
two isoforms were expressed in distinct cell types.
Glandular epithelial cells expressed AP-2a , while
myoepithelial cells expressed AP-2g . - a  and ERBB2
levels were weakly but significantly correlated. In
undifferentiated invasive carcinoma occasional co-
expression of the two AP-2 isoforms was noted (Friedrichs
et al, 2005). Interestingly, most breast cancer cell lines
which overexpress ERBB2, overexpress both AP-2a  and
AP-2g .
Finally, the relation between AP-2a  gene
methylation and expression was analyzed in breast cancer
cells and a panel of normal breast, DCIS and IC samples
(Douglas et al, 2004). AP-2a  gene was unmethylated in
most normal mammary epithelial cells and DCIS. AP-2a
protein was detected in the nuclei of both these types of
cells by IHC, with a tendency for overexpression in DCIS.
In contrast, in 75% of invasive carcinoma AP-2a  was
hypermethylated and the protein was undetectable. These
observations do not exclude an association between AP-2
and ERBB2 overexpression during breast cancer
progression. Indeed, ERBB2 was overexpressed in a high
proportion of DCIS (van de Vijver et al, 1988), while less
than 30% of IC overexpress the gene.
In summary, AP-2 isoforms are expressed in healthy
human breast cells, possibly in different cell types. These
cells express low levels of p185erbB2. AP-2 and ERBB2
expression was increased in DCIS. Three out of four IHC
analysis observed a tendency for a correlation AP-2 and
p185erbB2 levels in invasive carcinomas.
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Figure 3. Suppression of AP-2a  and AP-2g  expression downregulates ERBB2 transcript level in BT-474 cells. Cells cultured in 6-well
dishes were transfected on day 0 and 3 by 150nM siRNA directed against AP-2a nd/ or -g  transcripts. Control cells were
transfected with siRNA directed against luciferase mRNA. RNA and proteins were extracted after 2, 3 or 4 days of treatment. A.
Detection by western blotting of AP-2a  and AP-2g  levels in 20mg of total proteins from cells transfected with the siRNAs. Ku protein
served as control for the protein amount charged on the gel. B. Real time RT-PCR for AP-2a , AP-2g , ErbB2, VEGF (AP-2 target gene)
and B2M (standard gene) transcripts was performed on 1mg of total RNA from cells transfected with AP-2a  siRNA. The standardized
transcript levels were reported to the values obtained in control cells transfected with the luciferase siRNA. C. Same exper ments
performed on cells transfected with AP-2g  siRNA. D. Same experiments performed on cells transfected with AP-2a  and AP-2g  siRNA.
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C. Transgenic overexpression of AP-2 in
mice mammary gland
Mammary targeted overexpression of AP-2a
inhibited the development of the gland. The expression
level of Neu, the mice ERBB2 ortholog, was not modified
by AP-2a  overexpression (Zhang et al, 2003). Transgenic
overexpression of AP-2g  elicited hyper-proliferation of the
epithelial cells, which was counterbalanced by increased
apoptosis, the sum of these effects leading to hypoplesia of
the gland. In these mice the transgene did induce a slight
increase in Neu expression (Jäger et al, 2003).
However, the failure of AP-2 to stimulate Neu g ne
expression in mice mammary gland does not imply that
the human ERBB2 is not regulated by these transcription
factors. Indeed, as we have mentioned above, the AP2BS
are missing from the mice Neu promoter (Figure 2).
The results of the experiments on the role of AP-2
transcription factors on ERBB2 gene overexpression in
breast cancer cells are summarized in Table 1. In breast
cancer cell lines AP-2 factors stimulate ERBB2 promoter
activity. The factors are bound to the endogenous ERBB2
promoter and their down regulation inhibits the expression
of the endogenous gene. Thus, in breast cancer cell lines,
experimental evidence clearly indicates that AP-2 factors
stimulate ERBB2 gene transcription. With one exception, a
positive correlation was also reported between AP-2 and
p185erbB2 levels in primary breast cancers. As discussed
above, the null effect of AP-2 overexpression on Neu
expression in transgenic mice was probably due to the
absence of AP2BS in the rodent promoter. These results
indicate that AP-2 factors do contribute to ERBB2 gene
overexpression in some human breast cancers.
VI. ERBB2 overexpression in non-
breast cancer cells
The transcriptional mechanisms responsible for the
increased ERBB2 expression in cancers others than the
breast are poorly understood. We decided to use our
knowledge on breast cancer cells to understand the
mechanisms leading to ERBB2 gene overexpression in
non-breast human cancer cells. We used three prostate,
two ovary, five colon and seven pancreas cancer cell lines.
To start, we compared the transcript and protein levels
with the gene copy number. Next, we compared ErbB2
transcript and protein levels with those of AP-2 protein
levels and DNA binding. Finally, we analyzed the activity
of the ERBB2 promoter fragments which have been
previously characterized in breast cancers (Vernimmen et
al, 2003b).
We compared ERBB2 gene copy number, mRNA and
protein levels in the non-breast cancer cells with those of
well characterised breast cancer cells. ERBB2 gene
amplification was detected only in SKOV-3 ovary cancer
cells, where the amplification has been described
previously (King et al, 1992). These cells contained the
highest amounts of ErbB2 transcripts, comparable with
those measured in breast cancer cells with a similar degree
of gene amplification. Variable amounts of ErbB2 mRNA
were detected in the other cells we have analyzed. The
ErbB2 transcript levels in one colon cancer (COLO320)
and in HepG2 liver cancer cells were comparable to those
of ZR-75-1 breast cancer cells, which overexpress ERBB2
with a normal diploid set of genes.
The expression levels differed significantly between
cells derived from the same cancer type (Table 2). So,
ErbB2 mRNA levels were about seven times higher in
LNCaP than in PC-3 prostate cancer cells. The difference
between ErbB2 mRNA content in COLO320 and HTm29
colon cancer cells was thirteen fold. Pancreas cancer cells
presented a 40-fold difference between the cells
expressing the highest and the lowest amounts of the
transcripts.
P185erbB2 was detected by western blot in the majority
of the analyzed cells. Protein and mRNA levels were in
good agreement in the non-breast cancer cells, with the
exception of colon cancer cells (Table 2) (Vernimmen et
al, 2003b).
Next we compared AP-2 and p185erbB2 levels in the
non-breast cancer cell lines to find out if the
overexpression of the transcription factors contributes to
ERBB2 overexpression. Contrary to breast cancer cells,
AP-2 and p185erbB2 levels were not correlated in the non-
breast cancer cells. Strikingly, HepG2 cells expressed fair
amounts of erbB2 mRNA cells but were devoid of AP-2
(Vernimmen et al, 2003b).
In order to identify the factor(s) responsible for the
increased ERBB2 expression in non-breast cancer cells, we
compared the activity of ERBB2 promoter fragments in
couples of cells of the same origin expressing low and
high levels of the transcript. This approach lead to the
identification of AP-2 and ETS factors involvement in
ERBB2 overexpression in breast cancer cells. We could
carry out these experiments only in ovary and colon cancer
cells, because of very low transfection efficiencies of the
other cell types. Figures 4 B-E summarize our results
(Vernimmen et al, 2003b). The differences in promoter
fragments activities between breast and non-breast cancer
cells are striking. In ERBB2 overexpressing breast cancer
c lls, the activity of the promoter fragments from vectors 2
and 4 was maximal, when compared to minimal promoter
from vector 1. This activating potential is specific to
ERBB2 overexpression since the activity of all four
promoter fragments were similar in breast cancer cell lines
expr s ing low levels of the gene. Thus, the activating
potential of promoter fragments contained in vectors 2 and
4 reflect the endogenous ERBB2 expression level in breast
ancer cells (Figure 4B). In contrast, all promoter
fragments displayed comparable activities in HCT116
(Figur  4C) and in COLO320 cells (Figure 4D), in spite
of the 3 fold difference in their ErbB2 mRNA content. In
the ovary cancer cells the activity of the 6kb promoter
fragment was higher in OVCAR-3 (Figure 4E) than in
SKOV-3 cells (Figure 4F), while only the latter
overexpress ERBB2.
The low AP-2 levels might explain the low activity
of the p716-LUC vector in colon and ovary cancer cells
since AP-2 binding drives the activity of this fragment.
These r sults indicate that different mechanisms lead to
ErbB2 mRNA upregulation in cancerous cells of different
origins.
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The promoter fragments we have analyzed do not
contain the sequences responsible for increased ERBB2
gene expression in colon and ovary cancer cells. It is
possible that the transcription factors responsible for the
differences in transcription levels recognize sequences
outside the fragments we have studied.
Another possibility is that, contrary to breast cancer
cells, post-transcriptional mechanisms might be
responsible for the increased ErbB2 mRNA and protein
levels in the ovary and colon cancer cells we have
analyzed. Indeed SKOV-3 ovary carcinoma cells express a
variant ErbB2 mRNA with an extended half-life (Doherty
et al, 1999). These mechanisms will have to be taken into
account for the understanding of ERBB2 gene expression
regulation in non-breast cancer cells.
VII. Conclusions
P185erbB2 contributes to mammary carcinogenesis if
present in very high amounts, reached by the combination
of gene amplification and increased transcription rates. In
other tumours, increased protein levels, in the highest
range of the levels measured in breast cancers without
gene amplification, might be sufficient for cancer
progression, probably in cooperation with other oncogenic
signalling pathways. Our results indicate that different
me hanisms are responsible for increased receptor content
in non-breast cancer cells and in breast cancer cells. These
mechanisms are not known at present.
Recent data indicate that non-breast cancer cells
might become resistant to chemotherapy by upregulating
ERBB2 expression. Thus, understanding the mechanisms
r sponsible for the increase in p185erbB2 levels in different
cancer cells is important for the development of more
efficient therapeutic strategies for cancerous and non
cancerous diseases involving this protein.




Increased AP-2-a  and -g  levels in cells
overexpressing ERBB2
Bosher et al, 1995
Promoter activity AP-2-a  and -g  stimulate ERBB2 promoter
fragments containing AP-2 binding sites
Bosher et al, 1995; Grooteclaes et al,
1999; Vernimmen et al, 2003a
Mutation of AP-2 binding sites inhibits
ERBB2 promoter activity
Bosher et al, 1995, 1996; Vernimmen
et al, 2003a
DN-AP2 inhibits ERBB2 promoter activityDelacroix et al, 2005
Endogenous ERBB2 promoter AP-2 binding endogenous promoter proven
by ChIP
AP-2-a  and -g  directed siRNAs down-
regulate ERBB2 expression
Begon et al, 2005
Delacroix et al, 2005
Delacroix in preparation
Immunohistochemistry on primary human breast cancer sections
p185erbB2, AP-2a  and AP-2g Positive correlation between AP-2a  and
AP-2g  levels and p185erbB2 levels
Tumer et al,1998
p185erbB2/ AP-2a Positive correlation in a fraction of the
tumors
Pellikainen et al, 2004
p185erbB2 AP-2a Week correlation between AP-2a  and
p185erbB2 levels
Friedrichs et al, 2005
p185erbB2 and AP-2a  + AP-2g Negative correlation Gee et al,1999
AP-2 overexpression in the mammary gland of transgenic mice
AP-2a The development of the gland is inhibitedZhang et al, 2003
AP-2g Increased proliferation and apoptosisJäger et al, 2003
Table 2. Differences in ErbB2 mRNA and protein levels in human cancer cell lines of different origins. The transcript
levels were measured by quantitative RT-PCR, while the protein levels were estimated by western blotting (adapted from
Vernimmen et al, 2003b). For each cancer type two cell lines are presented, one containing the lowest the second the
highest amounts of ErbB2 mRNA and protein. For each cancer type, the lowest transcript and protein amounts were
considered as equal to one. The relative increase in expression was calculated by dividing the highest values by the
smallest values measured in cells from the same cancer type.The asterisks indicate an underestimated value for SKOV-3
protein level, because of autoradiograph saturation.
Origin Ovary Prostate Colon Pancreas












mRNA 1 60 1 7.3 1 13 1 42.5
Protein 1 13** 1 7.5 1 0.5 1 23
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Figure 4. ERBB2 promoter activity in human cancer cells of different origins. A. Reporter vectors used in this study containing the
luciferase (LUC) cDNA under the transcriptional control of 215 (1), 716 (2), 3798 (3) and 6007 (4) bp fragments of the human ERBB2
promoter. B. Relative luciferase activities induced by reporter vectors 2, 3 and 4 transfected into BT-474 breast cancer cells
overexpressing ERBB2, reported to the activity induced by vector 1 considered as equal to one (Delacroix et al, in press). C. R lative
luciferase activities induced by reporter vectors 2, 3 and 4 transfected into HCT116 colon cancer cells reported to the activity induced by
vector 1 considered as equal to one. D. Relative luciferase activities induced by reporter vectors 2, 3 and 4 transfected into COLO 320
colon cancer cells, reported to the activity induced by vector 1 considered as equal to one. E. Relative luciferase activities induced by
reporter vectors 2, 3 and 4 transfected into OVCAR-3 ovary cancer cells reported to the activity induced by vector 1 considered as equal
to one. F. Relative luciferase activities induced by reporter vectors 2, 3 and 4 transfected into SKOV-3 ovary cancer cells overexpressing
ERBB2 reported to the activity induced by vector 1 considered as equal to one (Vernimmen et al, 2003b).
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